drugset / Trial / NCT00002361

Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors

NCT00002361 ↗

Phase 2 Completed 30 enrolled Merck Sharp & Dohme LLC
Treatment

Summary

The purpose of this study is to see if it is safe and effective to give an anti-HIV drug combination containing indinavir and ritonavir to HIV-positive patients who have failed previous treatment with protease inhibitors.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject INDINAVIR ANHYDROUS Other / unclassified 800 mg —
Subject Ritonavir Other / unclassified 200 mg —